Ovid Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.3M | $566,000 | $392,000 | $1.5M | $208.4M |
| Research and development | $25.6M | $36.8M | $28.6M | $24.6M | $46.9M |
| Operating expenses | $49.7M | $62.5M | $59.7M | $57.1M | $84.2M |
| Operating income | -$42.4M | -$61.9M | -$59.3M | -$55.5M | $124.2M |
| Pretax income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | $124.2M |
| Income tax expense | $0 | $0 | $0 | $0 | $1.3M |
| Net income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | $122.8M |
| Balance Sheet | |||||
| Cash and equivalents | $13.2M | $26.3M | $27.0M | $44.9M | $187.8M |
| Current assets | $74.4M | $55.9M | $109.6M | $131.4M | $190.5M |
| Total assets | $150.9M | $92.2M | $144.0M | $155.3M | $194.5M |
| Current liabilities | $8.3M | $10.5M | $11.5M | $7.0M | $14.8M |
| Total liabilities | $20.3M | $23.9M | $56.2M | $23.0M | $14.8M |
| Stockholders' equity | $130.7M | $68.2M | $87.8M | $132.3M | $179.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$38.3M | -$56.0M | -$45.8M | -$55.2M | $118.6M |
| Depreciation and amortization | $273,000 | $613,000 | $568,000 | $512,505 | $237,079 |
| Stock-based compensation | $4.8M | $6.3M | $7.3M | $6.6M | $5.1M |
| Capital expenditure | $0 | $71,000 | $40,000 | $1.2M | $184,008 |
| Free cash flow | -$38.3M | -$56.0M | -$45.8M | -$56.5M | $118.4M |
Shares outstanding 186.6M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.